It took 13 years, but melanoma patients now have access to a new treatment at long last. On March 25, the FDA approved Yervoy (also known as Ipilimumab) to treat advanced melanoma. It is the first approved therapy proven to extend the lives of late-stage melanoma patients and the Melanoma Research Foundation supported some of the early research that led to the development of this drug.
People with melanoma have urgently needed a new treatment option like this, but more work lies ahead. Advances like Yervoy demonstrate the need to intensify research efforts, particularly studies that combine therapies, to develop successful treatments.